Stock News and Filings Feed


Add 506820
to your dashboard

Pharma Newsletter- July 24 to July 28, 2017

2017-07-29 indiainfoline
This week, “AstraZeneca Pharma India has received a one month extension from its parent firm AstraZeneca UK to sell anti-bacterial drug Meronem in India. The parent company has given extension due to delay in the divestment of AstraZeneca’s global rights to Meronem.”

AstraZeneca gets extension for withdrawal of Meronem till Aug 31

2017-07-28 thehindubusinessline
AstraZeneca Pharma India has got another month’s extension from its parent firm AstraZeneca UK to sell anti-bacterial drug Meronem in India due to delay in the divestment of AstraZeneca’s global rights to Meronem.

AstraZeneca gets extension for Meronem withdrawal till Aug 31

2017-07-28 moneycontrol
AstraZeneca Pharma India has got another month's extension from its parent firm AstraZeneca UK to sell anti-bacterial drug Meronem in India due to delay in the divestment of AstraZeneca's global rights to Meronem.

AstraZeneca Pharma India Limited - Updates

2017-07-28 feedproxy.google

AstraZeneca Pharma India Limited - Results

2017-07-25 feedproxy.google

AstraZeneca Pharma India Limited - Updates

2017-07-22 feedproxy.google

Market ends with small losses

2017-06-21 indiainfoline
Key benchmarks ended with minor losses as negative global cues spoiled investors sentiment. The barometer index, the S&P BSE Sensex, fell 13.89 points or 0.04% to 31,283.64, as per the provisional closing data. The Nifty 50 index fell 16.40 points or 0.17% to 9,637.10, as per the provisional closing data.

Astrazeneca Pharma India gains after DCGI nod for asthma drug

2017-06-16 indiainfoline
AstraZeneca Pharma India rose 1.47% to Rs 933 at 11:02 IST on BSE after the company said it received import and market permission in Form 45 from Drug Controller General of India for FDC of inhalation powder.

Astrazeneca Pharma India receives Import and Market permission for Asthma drug

2017-06-15 indiainfoline
FDC of Budesonide 320 µg + Formoterol Fumarate Dihydrate 9 µg inhalation powder (Symbicort® Turbuhaler® 320/9 µg) is a product of AstraZeneca global and is indicated in the regular treatment of Asthma where use of combination of inhaled regular corticosteroid & long acting ß-agonist is appropriate and patients with moderate to severe COPD with frequent symptoms and a history of exacerbations

MSCI indices rejig takes effect today

2017-05-31 thehindubusinessline
From Thursday, Indian Oil Corporation and Rural Electrification Corporation will be part of the MSCI Global Standard Index while Divi’s Laboratories will be out.

6
shares
Sensex hits all-time high in record-setting spree

2017-05-16 in.reuters
Indian shares continued their record-setting spree on Tuesday, hitting all-time highs for the third time in five sessions, as investors remained bullish about the prospects of a good monsoon.

IOC, Rural Electrification rise on MSCI index addition

2017-05-16 thehindubusinessline
Shares of Indian Oil Corp Ltd and Rural Electrification Corp rose 1-1.2 per cent, while drug-maker Divi's Laboratories Ltd fell 0.4 per cent.

AstraZeneca Pharma India Limited - Results

2017-04-25 feedproxy.google

Cancer drug prices slashed up to 86% in a year: NPPA

2017-03-06 thehindubusinessline
Drug pricing regulator NPPA has slashed price of cancer drugs by up to 86 per cent since March last year providing relief to lakhs of patients.

AstraZeneca Pharma India Limited - Updates

2017-02-24 feedproxy.google

AstraZeneca Pharma India Limited - Results

2017-01-23 feedproxy.google

Fintel IR - Find the Right Investors for Your Company, Instantly!

Fintel IR combines the comprehensive Fintel ownership database with machine learning to provide advanced tools to make investor outreach fast and easy. Learn more now!